Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(13%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_2
8
100%

Phase Distribution

0

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
8(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Other(1)

Detailed Status

Completed6
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 28 (100.0%)

Trials by Status

active_not_recruiting113%
completed675%
unknown113%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

NCT00716066
completedphase_2

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

NCT00793572
unknownphase_2

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

NCT00008307
completedphase_2

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

NCT00002552
completedphase_2

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

NCT00040872
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00716066Phase 2

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Active Not Recruiting
NCT00793572Phase 2

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Completed
NCT00008307Phase 2

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown
NCT00002552Phase 2

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Completed
NCT00040872Phase 2

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Completed
NCT00002547Phase 2

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Completed
NCT00002521Phase 2

Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Completed
NCT00002522Phase 2

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Completed

All 8 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
8